TAMPA, Fla., Feb. 21, 2019 (SEND2PRESS NEWSWIRE) — The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridioides difficile clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.
Clostridioides difficile is also known as C.difficile, C.diff, CDI (Clostridioides difficile infection), CDAD (Clostridioides difficile-associated disease) and formally called Clostridium difficile.
In the USA: Nearly half a million Americans suffer from Clostridioides difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention (CDC). Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. About 15,000 deaths were estimated to be directly attributable to C. difficile infections making it a very important cause of infectious disease death in the United States.
“The broad range of new therapies for Clostridium difficile (C.difficile) is being intensely studied in several essential global clinical trials. This continued research underpins the current clinical needs with both preventing and treating C.difficile,” stated Glenn S. Tillitson, Ph.D., FRSM, FCCP.
Individuals volunteer to participate in clinical trials in hopes of improving their own health, to access treatments that might not be available otherwise, often because they are new and not yet widely available. They help others by contributing to advances in medicine. There can also be potential risks participating in clinical trials and clinical studies. All of the known risks associated with a particular trial and or study will be discussed during the informed consent process. It will be thoroughly explained in the informed consent document that a volunteer will receive from the research staff prior to participating in any study.
To learn more about clinical research (e.g., Clostridioides difficile formally Clostridium difficile, also known as C.diff. C.difficile. CDI, CDAD) visit the U.S. Food and Drug Administration https://www.fda.gov/ or telephone 1-800-835-4709, and visit https://clinicaltrials.gov/.
“Clinical trials are vital to improving our knowledge about how best to prevent and treat C. difficile infections. Informing patients of clinical trials is important, and in recent years several clinical trials have led to significant improvements in the treatments available for patients with C. difficile infections. Clinical trials are a vital way of making progress in our search for new therapies to prevent and treat a CDI,” stated Mark Wilcox, MD, FRCPath, Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology Leeds Teaching Hospitals, Professor of Medical Microbiology University of Leeds Institute of Biomedical and Clinical Sciences, Lead on Clostridium difficile for Public Health England, UK.
About the U.S. Food and Drug Administration (FDA):
The FDA is responsible for protecting the public health by assuring that foods are safe, wholesome, sanitary and properly labeled; ensuring that human and veterinary drug, and vaccines and other biological products and medical devices intended for human use are safe and effective. FDA’s responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico, Guam, the Virgin Islands, American Samoa, and other U.S. territories and possessions.
About ClinicalTrials.gov:
ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.
About the C Diff Foundation:
The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission of providing education for C.difficile infection prevention, treatments, environmental safety and support through research being conducted by the government, industry, and academia and provide better advocacy on behalf of patients, healthcare professionals, and researchers worldwide.
For information please visit http://www.cdifffoundation.org/.
###
Media Contact:
Angelo Ortiz
CDIFF Foundation
(727) 205-3922
Angelo.ortiz@cdifffoundation.org
###
MEDIA ONLY CONTACT:
(not for print or online)
*PHOTO for media: Send2Press.com/300dpi/19-0221s2p-cdiff-aware-300dpi.jpg
News Source: C Diff Foundation
